ArticleJournal of human immunity2027

Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety.

V Koneti Rao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.